Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine

NCT01848873 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 756

Last updated 2013-05-08

No results posted yet for this study

Summary

To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.

Conditions

  • Essential Hypertension

Interventions

DRUG

Amlodipine

amlodipine 5mg daily

DRUG

amlodipine-FA tablet, low dose group

5mg amlodipine combined with 0.4 mg of folic acid, daily.

DRUG

amlodipine-FA tablet ,high dose group

amlodipine 5mg and folic acid 0.8mg daily

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER
  • Chinese PLA General Hospital

    collaborator OTHER
  • Capital Medical University

    collaborator OTHER
  • Fudan University

    collaborator OTHER
  • Ruijin Hospital

    collaborator OTHER
  • Nanchang University

    collaborator OTHER
  • First Affiliated Hospital of Fujian Medical University

    collaborator OTHER
  • First Affiliated Hospital of Harbin Medical University

    collaborator OTHER
  • China Medical University, China

    collaborator OTHER
  • Xi'an Jiaotong University

    collaborator OTHER
  • Xuzhou Medical University

    collaborator OTHER
  • Anhui Medical University

    collaborator OTHER
  • Huazhong University of Science and Technology

    collaborator OTHER
  • West China Hospital

    collaborator OTHER
  • Guangdong Provincial People's Hospital

    collaborator OTHER
  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER
  • Shenzhen Ausa Pharmed Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Yong Huo, MD · Peking University First Hospital, Beijing, CHINA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01848873 on ClinicalTrials.gov